InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation...

|By:, SA News Editor

InterMune (ITMN +5%) rallies after Brean Murray calls it a top 2012 pick, citing a low valuation and strong German demand for InterMune's Esbriet lung disease drug. Brean's call is more than offsetting a PT cut from Goldman (Neutral), which thinks uncertainty over future Esbriet pricing "creates an overhang that is likely to persist through the middle of 2012."